SBI Securities’s ABVC BioPharma ABVC Stock Holding History

SBI Securities’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-483	Closed	-$1.07K	–	4186
2025 Q2	$1.07K	Buy	483 +23	+5%	+$31	﹤0.01%	2648
2025 Q1	$488	Sell	460 -202	-31%	-$123	﹤0.01%	2881
2024 Q4	$391	Buy	+662	New	+$369	﹤0.01%	2985

Other funds holding ABVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities's ABVC Position: Q3 2025 in Review

SBI Securities sold out of ABVC BioPharma (ABVC) in Q3 2025, closing a stake of 483 shares — an estimated $1.07K sold.

SBI Securities first reported a position in ABVC in Q4 2024 and held it in 3 quarters. The position peaked at $1.07K in Q2 2025. 14 funds tracked by Wall St. Rank hold ABVC as of Q3 2025.

SBI Securities reported no remaining ABVC BioPharma position as of Q3 2025 after selling out during the quarter.
SBI Securities sold 483 ABVC BioPharma shares in Q3 2025, an estimated $1.07K.
SBI Securities first reported a position in ABVC BioPharma in Q4 2024 and held it in 3 quarters.
SBI Securities's ABVC BioPharma position peaked at $1.07K in Q2 2025.
14 funds tracked by Wall St. Rank held ABVC BioPharma as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.